Cerliponase alfa

Drug Profile

Cerliponase alfa

Alternative Names: BMN 190; Brineura; rhTPP1

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator BioMarin Pharmaceutical
  • Class Enzymes; Peptide hydrolases; Recombinant proteins
  • Mechanism of Action Tripeptidyl peptidase 1 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuronal ceroid lipofuscinosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neuronal ceroid lipofuscinosis

Most Recent Events

  • 04 May 2017 Launched for Neuronal ceroid lipofuscinosis (In adolescents, In children) in USA (Intracerebral)
  • 27 Apr 2017 BioMarin Pharmaceutical anticipates launch of cerliponase alfa in Neuronal ceroid lipofuscinosis (In adolescents, In children) in USA
  • 27 Apr 2017 Registered for Neuronal ceroid lipofuscinosis (In adolescents, In children) in USA (Intracerebral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top